Business Wire

The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

Share

Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced today The Lancet Respiratory Medicine (“Lancet”), an internationally trusted, peer-reviewed source of clinical, public health, and global health knowledge, published positive results from Humanigen’s LIVE-AIR Phase 3 randomized, controlled trial of lenzilumab in hospitalized COVID-19 patients, as well as an independent expert commentary. The Lancet paper concludes “LIVE-AIR showed that lenzilumab treatment of hospitalised patients with COVID-19 can improve the likelihood of survival without the need for mechanical ventilation, with a safety profile similar to that of placebo.”2

“Publication of LIVE-AIR results in this peer-reviewed medical journal is a major achievement. Our goal was to demonstrate that lenzilumab, a variant-agnostic therapy, could address the unmet need in treatment of COVID-19 patients by reducing death or mechanical ventilation. The results describe the positive impact lenzilumab has on improving survival without the need for invasive mechanical ventilation in COVID-19 patients upon hospitalization,” said Cameron Durrant, Chairman and CEO, Humanigen. “As the paper describes ‘60% of LIVE-AIR patients were on room air or low-flow oxygen support. … (Raising) the possibility that lenzilumab might be positioned for use before ICU admission and progression of respiratory failure requiring high-flow oxygen and non-invasive or invasive ventilation.’”2

“This study of the treatment to prevent hyperinflammatory immune response that occurs in some patients infected with SARS-CoV-2 is important,” said Zelalem Temesgen, M.D., Mayo Clinic infectious disease researcher and principal investigator. “The need is great for more therapies for newly hospitalized patients prior to respiratory failure to reduce mortality or mechanical ventilation.”

Lenzilumab is not authorized, or approved, in any country.

“One of the key components of the detrimental hyperinflammatory response in COVID-19 is granulocyte-macrophage colony-stimulating factor (GM-CSF). ... excessive GM-CSF production can contribute to the dysregulated immune response in severe COVID-19, in which, upstream of IL-1 and IL-6, activated T cells target neutrophils and macrophages. Agents that interfere with its actions have high plausibility for benefit, not just in COVID-19, but in other acute inflammatory conditions,”1 noted the commentary.

The Lancet paper notes differences in CRP levels for LIVE-AIR patients compared to those of clinical trials for another immunomodulator to suggest these “findings might indicate the therapeutic potential of targeting a single upstream cytokine earlier in the disease process, guided by baseline CRP. ... The study contributes to the emerging body of evidence about how CRP concentrations relate to the pathogenesis of COVID-19 and to patient and treatment selection.”2 Related to the value of a CRP-guided approach to treatment of COVID-19 patients, the commentary noted “further study of a CRP-guided approach, possibly targeting patients with lower CRP concentrations, earlier in their disease course, ... could therefore be warranted.”1

For hospitalized patients, “we now know that targeting the dysregulated host response is of greater value than targeting the virus.”1 The high level of uncertainty and concern surrounding the emergence of the Omicron variant highlights the ongoing need for variant-agnostic therapies.

About the LIVE-AIR, Phase 3 Study of Lenzilumab

This study was a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial for the treatment and prevention of serious and potentially fatal outcomes in patients hospitalized with COVID-19 pneumonia. The primary objective was to assess whether lenzilumab, in addition to other treatments, which included dexamethasone (or other steroids) and/or remdesivir, could prevent or alleviate the immune-mediated ‘cytokine storm’ and improve survival without ventilation, or ‘SWOV’ (sometimes referred to as ‘ventilator-free survival’). SWOV is a composite endpoint of time to death and time to invasive mechanical ventilation (IMV) and SWOV is an important clinical endpoint that measures not only mortality, but the morbidity associated with mechanical ventilation. Approximately 94% of patients received dexamethasone (or other steroids), 72% received remdesivir, and 69% received both.

The LIVE-AIR study enrolled 520 patients in 29 sites in the US and Brazil who were at least 18 years of age; experienced blood oxygen saturation (SpO2) of less than or equal to 94%; or required low-flow supplemental oxygen, or high-flow oxygen support, or non-invasive positive pressure ventilation; and were hospitalized but did not require IMV. Following enrollment, subjects were randomized to receive three infusions of either lenzilumab or placebo, with each infusion separated by eight hours over a 24-hour period. The LIVE-AIR study achieved its primary endpoint of survival without ventilation measured through day 28 following treatment (HR: 1.54; 95%CI: 1.02-2.32, p=0.040).

About Lenzilumab

Lenzilumab is a proprietary Humaneered® first-in-class monoclonal antibody that has been proven to neutralize GM-CSF, a cytokine of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome, or cytokine storm, associated with COVID-19 and other indications. Lenzilumab binds to and neutralizes GM-CSF, consequently improving outcomes for patients hospitalized with COVID-19. Humanigen believes that its GM-CSF neutralization has the potential to reduce the hyper-inflammatory cascade known as cytokine release syndrome common to chimeric antigen receptor T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD).

In CAR-T, lenzilumab successfully achieved the pre-specified primary endpoint at the recommended dose in a Phase 1b study with Yescarta® in which the overall response rate was 100% and no patient experienced severe cytokine release syndrome or severe neurotoxicity. Based on these results, Humanigen plans to test lenzilumab in a randomized, multicenter, potentially registrational, Phase 2 study to evaluate its efficacy and safety when combined with other commercially available CD19 CAR-T therapies in non-Hodgkin lymphoma. Lenzilumab will also be tested to assess its ability to prevent and/or treat aGvHD in patients undergoing allogeneic hematopoietic stem cell transplantation.

A study of lenzilumab is also underway for patients with chronic myelomonocytic leukemia (CMML) exhibiting RAS pathway mutations. This study will build on evidence from a Phase 1 study, conducted by Humanigen, that showed RAS mutations are associated with hyper-proliferative features, which may be sensitive to GM-CSF neutralization.

About Humanigen

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”) is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’. Lenzilumab is a first-in-class antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). Results from preclinical models indicate GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm. Early in the COVID-19 pandemic, investigation showed high levels of GM-CSF secreting T cells were associated with disease severity and intensive care unit admission. Humanigen’s Phase 3 LIVE-AIR study suggests early intervention with lenzilumab may prevent consequences of a full-blown cytokine storm in hospitalized patients with COVID-19. Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Marketing Authorization. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as aGvHD in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding: Humanigen’s beliefs as to the potential benefits of lenzilumab as a treatment for hospitalized COVID-19 patients; its beliefs as to the potential of lenzilumab to improve patient survival when used before ICU admission and progression of respiratory failure; statements regarding the therapeutic potential of targeting a single upstream cytokine earlier in the COVID-19 disease process; its efforts to request and receive Conditional Marketing Authorization for lenzilumab in COVID-19 in the UK and other territories; and its other plans to initiate or participate in planned clinical trials and otherwise explore the effectiveness of lenzilumab and other candidates in its development portfolio as therapies for other inflammation and immune-oncology indications.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in the company’s lack of profitability and need for additional capital to conduct its business; its dependence on partners to further the development of its product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; challenges associated with manufacturing and commercializing a biologic such as lenzilumab; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in Humanigen's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. The Company undertakes no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

References

  1. Leavis, H. et al. (2021). Comment: Stimulating severe COVID-19: the potential role of GM-CSF antagonism. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(21)00539-7
  2. Temesgen, Z. et al. (2021). Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(21)00494-X

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Humanigen Investor Relations
Ken Trbovich
Humanigen
trbo@humanigen.com
650-410-3206

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ekata Expands Account Opening Solution to Help Online Businesses Assess Risk at Account Creation19.1.2022 14:00:00 CET | Press release

Ekata, a global leader in digital identity verification, today expanded its account opening solutions to help online businesses worldwide quickly identify and flag risky account sign-ups. Powered by a proprietary data set and machine learning, Ekata's account opening solutions assess the risk of new accounts in real-time, enabling businesses to create streamlined onboarding experiences for legitimate customers and reject or add friction to high-risk customers. Ekata’s new capabilities expand its existing account opening solution for financial services and fintech companies. Increasingly, fraud occurs earlier in the customer journey at the account creation stage, not just during transactions. In the past year alone, more than half of ecommerce companies experienced an increase in promotion abuse, with individuals creating multiple accounts to take advantage of limited-time promotions, causing significant loss to retailers. Marketplaces have also seen more malicious users impacting platf

Tinubu® Square Americas Names Jessica Mann as General Manager19.1.2022 14:00:00 CET | Press release

Tinubu® Square Group, the leading software provider for the Credit & Surety industry, has appointed Jessica Mann as General Manager of Tinubu Square Americas. Through its technology platform, Tinubu Square Americas processes CIRCA 50% of the bonds issued in the US. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005502/en/ Jessica MANN General Manager Tinubu Square Americas (Photo: Tinubu Square) In her new role, Jessica will implement the Group Business Strategic plan in the Americas, with responsibility over the P&L, the business growth in all defined market segments and products ensuring retention and nurturing of the customer base. Jessica Mann brings to Tinubu Square Americas her strong background in Surety management and underwriting, notably with her most recent role with Everest Insurance as Vice President, Head of Commercial Surety, where she led Everest’s expansion of its commercial surety business. She also h

KnowBe4 Finds U.S. Phishing Emails Focus on Password Alerts and Policy Changes While EMEA Focuses on Everyday Tasks19.1.2022 14:00:00 CET | Press release

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced the results of its Q4 2021 top-clicked phishing report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005245/en/ KnowBe4 Q4 2021 Top-Clicked Phishing Report Infographic (Graphic: Business Wire) “When comparing the results from the U.S. phishing emails to those in Europe, the Middle East and Africa (EMEA), email subjects in the U.S. appear to originate from the users’ organizations and are focused on security alerts related to passwords and internal company policy changes,” said Stu Sjouwerman, CEO, KnowBe4. “However, in EMEA, the top subjects are related to users’ everyday tasks and the subject lines appear to be more personalized to entice the user to click. As expected, we did see some phishing email subjects related to the holidays, especially holiday shopping in particular. Employees should rem

AMCS Acquires Utility Billing Software Company Utilibill to Enter the Global Water and Energy Sector19.1.2022 13:00:00 CET | Press release

AMCS, the leading global supplier of integrated software and vehicle technology for the environmental, recycling, and resource industries, today announced that it has acquired Utilibill, a leading Australian-based cloud billing platform for an undisclosed amount. This acquisition complements AMCS’ strategy of being a valued technology partner for customers on their journey to net-zero carbon, resource sustainability and the circular economy. Based in Melbourne, Utilibill is an Australian software company providing a leading edge, cloud-based utility billing platform. Founded 16 years ago by Igor Green and Morgan Duncan, Utilibill started serving telecommunications clients, before expanding into the energy market eight years ago. Utilibill has close to 100 employees including support centers in the Philippines and offices in the US serving more than 200 telecommunications, water, and energy utilities globally. “The seed of AMCS was an innovative recycling billing solution that incentivi

Personetics Secures Over $160 Million in 2021 and Accelerates the Global Expansion of its AI-Driven Personalization and Engagement Solutions for Financial Institutions With $85 Million Investment From Thoma Bravo19.1.2022 13:00:00 CET | Press release

Personetics, the leading global provider of financial-data-driven personalization and customer engagement solutions for banks and financial services providers, today announced it has raised $85m in growth funding from Thoma Bravo, a leading software investment firm. Personetics secured a total funding of over $160 million in 2021.Personetics is backed by Viola Ventures, Lightspeed Ventures, Sequoia Capital, Nyca Partners and Warburg Pincus. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005014/en/ Co-founders of Personetics, David Sosna (CEO, left) and David Govrin (COO, right) (Photo: Business Wire) Operating in a global market worth approximately $15 billion, Personetics’ AI-based engagement platform is becoming a market standard in financial-data-driven personalization, customer engagement and money management for global financial institutions across all channels. Personetics partners with financial institutions to

Lunaphore appoints Janis Taube, M.D., M.Sc., to Scientific Advisory Board19.1.2022 12:00:00 CET | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced the appointment of Janis M. Taube, M.D., M.Sc., a leading pathologist and expert on immunotherapy research, to its Scientific Advisory Board. As an advisor, Dr. Taube will provide strategic advisory support to Lunaphore’s scientific activities and product portfolio development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005555/en/ Janis Taube, M.D., M.Sc. (Photo: Lunaphore) “Janis is a trailblazer and highly regarded expert in pathology and immunotherapy research, and we are excited to work with her to build visibility of our products in laboratories around the world,” said Diego G. Dupouy, Ph.D., Chief Technology Officer of Lunaphore. “We are proud to have convened a world-class group of scientific advisors to help advance our scientific and product development strategy.” Dr. Taube is the D

Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI19.1.2022 12:00:00 CET | Press release

Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI. In this newly created role, she will focus on the application of artificial intelligence (AI), machine learning, and the design of protein structures in the discovery and development of novel drug candidates. Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer, Garry Pairaudeau. Professor Deane is one of the UK’s most accomplished bioinformaticians. She has held numerous senior roles at the University of Oxford, where she is currently Professor of Structural Bioinformatics and leads the University’s Protein Informatics group. She will maintain both of these roles, in addition to her role at Exscientia. Prior to this, Professor Deane was Deputy Executive Chair of the Engineering and Physical Sciences Research Council at UK Research and Innovation (UKRI). She has played an active role during the COVID-19 pandemic as the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom